Research is the answer to one day making FA a treatable, manageable disease. Here, you'll discover the most recent strides in FA research and activities funded by FCF. Every quarter, we'll bring you updates on newly funded grants, ongoing projects, and significant milestones.
Directory

Sharon Cantor
Associate Professor | PhD
My laboratory focuses on understanding how tumor suppressor proteins function to maintain genomic integrity and suppress cancer. In particular, we focus on the hereditary breast and ovarian cancer genes, BRCA1, BRCA2 and the BRCA1-associated helicase, FANCJ (BACH1/ BRIP1). Bi-allelic loss of these genes also causes Fanconi anemia (FA), a rare chromosomal instability and cancer syndrome. Our work on FANCJ revealed that DNA repair defects underlie both hereditary breast cancer and FA. Currently, we are employing biochemical and whole-genome screening technologies, to uncover mechanisms regulating DNA repair choice and how cancer cells evade toxic chemotherapies.
FA Research Projects
Year | Project |
---|---|
2020 | A small molecule approach to overcome replication dysfunction in FA |
The Latest
News & Events


What started as a small local fundraiser in memory of an incredible little girl has evolved into a powerful movement uniting friends, family, neighbors, and supporters in pursuit of a future with better outcomes and brighter hope for families affected by FA.

We’re thrilled to announce a new partnership between the Fanconi Cancer Foundation (FCF) and the American Cancer Society (ACS): the Fanconi Cancer Foundation Discovery Boost Grant. This grant program will fuel innovative research aimed at preventing, detecting, and treating cancers associated with Fanconi anemia (FA).